H.R. 4299, Improving Regulatory Transparency for New Medical Therapies Act

Cost Estimate
June 26, 2014

As ordered reported by the House Committee on Energy and Commerce on June 10, 2014

H.R. 4299 would modify the administrative procedures followed by the Department of Justice in regulating new drugs that are already approved by the Food and Drug Administration and in authorizing drugs to be used in clinical trials. The legislation would aim to streamline the current review and approval process. CBO estimates that implementing the bill would have no significant costs to the federal government. Enacting the legislation would not affect direct spending or revenues; therefore, pay-as-you-go procedures do not apply.

H.R. 4299 contains no intergovernmental or private-sector mandates as defined in the Unfunded Mandates Reform Act and would impose no costs on state, local, or tribal governments.